Moderna (MRNA)
NASDAQ: MRNA · Biotechnology · Cambridge, MA
Our rating: Cautious
Cautious reaffirmed at $269.00, high conviction, November 9, 2026.
Breaks if: The cautious call would need revisiting if Moderna's trailing twelve-month revenue reaches $4 billion or above within the next four quarterly filings — roughly double the current run-rate — alongside a narrowing of free cash flow burn to better than negative $800 million, together signaling a credible floor in the revenue decline and a cost structure beginning to right-size. If the stock sustains a price above $350 for more than thirty consecutive trading days without a corresponding improvement in those fundamentals, that would equally signal the market is pricing in catalysts not yet visible in the filings.
Key figures
| Market value | $78.9B |
|---|---|
| Revenue, last 12 months | $2.5B |
| Net income, last 12 months | −$2.8B |
| Free cash flow, last 12 months | −$2.0B |
| Price to earnings | n/a |
| Free cash flow yield | −2.5% |
| Dividend yield | 0.0% |
| Operating margin | −116.0% |
| Return on equity | −34.5% |
| Beta to the S&P 500 | 1.52 |
| Volatility, annualized | 133.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.3B | 29.2% | $0.38 | −$1.6B |
| June 30, 2026 | $145M | 2.1% | $-1.97 | −$563M |
| March 31, 2026 | $389M | 260.2% | $-3.40 | −$692M |
| December 31, 2025 | $678M | −29.8% | $-2.11 | $891M |
| September 30, 2025 | $1.0B | −45.4% | $-0.51 | −$880M |
| June 30, 2025 | $142M | −41.1% | $-2.13 | −$922M |
| March 31, 2025 | $108M | −35.3% | $-2.52 | −$1.2B |
| December 31, 2024 | $966M | −65.6% | $-2.91 | $303M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.12B: Claude 52%, Gemini 85%, Mistral 42%
- Diluted earnings per share are above zero: Claude 38%, Gemini 55%, Mistral 32%
- Free cash flow for the quarter is at least $0.89B: Claude 18%, Gemini 15%, Mistral 22%
57 ledger entries and 14 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.